scholarly journals Guar bread: acceptability and efficacy combined. Studies on blood glucose, serum insulin and satiety in normal subjects

1981 ◽  
Vol 46 (2) ◽  
pp. 267-276 ◽  
Author(s):  
P. R. Ellis ◽  
E. C. Apling ◽  
A. R. Leeds ◽  
N. R. Bolster
Keyword(s):  
Blood Glucose ◽  
Guar Gum ◽  
Serum Insulin ◽  
Regression Line ◽  
Food Product ◽  
Normal Subjects ◽  
Predictive Score ◽  
Positive Correlation ◽  
Normal Volunteers ◽  
Significant Difference

1. Bread alone and supplemented with guar gum at three levels (50, 100 and 150 g/kg) was given to eleven non-diabetic subjects, and blood glucose and serum insulin were determined preprandialy, and at 30 min and 60 min after commencement of the meal. The satiating effect, up to 120 min, of the guar bread and its acceptability to the same group of normal volunteers was also studied.2. No significant differences in blood glucose were observed between control and guar breads at 30 min and 60 min, apart from 100 g guar/kg bread at 30 min (P < 0·05). A significant difference in serum insulin was indicated between: control and 50 (P < 0·02) and 150 (P < 0·02) guar/kg breads at 30 min; control and 50 (P < 0·05), 100 (P < 0·001) and 150 (P < 0·05) guar/ke breads at 60 min.3. There were no significant differences in the satiety scores for control and guar breads. Significant increases in satiety attributed to 150 g guar/kg bread were found when compared to: 50 g guar/kg bread immediately after eating (P < 0·05), 100 g guar/kg bread at 60 min (P < 0·02) and 50 and 100 g guar/kg breads at 120min (both P < 0·05).4. There was a positive correlation between hedonic score and relative replacement of guar (r 0·62, P < 0·001, n 44) and from the regression line it was found that 50 and 100 g guar/kg breads produced hedonic scores close to a neutral response of 5, whereas 150 g guar/kg bread at a predictive score of 6·3 appeared to be unacceptable to our subjects.5. Guar bread at the 100 g/kg level (59 g guar/kg bread) reduced the serum insulin by 48% at 60 min and is found to be an acceptable food product at this level of incorporation. However, more information is required to demonstrate the possible satiating potential of guar bread.

scholarly journals Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia

2000 ◽  
Vol 278 (1) ◽  
pp. G98-G104 ◽  
Author(s):  
C. K. Rayner ◽  
H. S. Park ◽  
S. M. Doran ◽  
I. M. Chapman ◽  
M. Horowitz
Keyword(s):  
Blood Glucose ◽  
Glucose Concentration ◽  
Guar Gum ◽  
Blood Glucose Concentration ◽  
Acute Effect ◽  
Saline Control ◽  
Significant Difference ◽  
Blood Glucose Concentrations ◽  
Pyloric Motility ◽  
Food Consumed

Recent studies suggest that the interaction between small intestinal nutrient stimulation and the blood glucose concentration is important in the regulation of gastric motility and appetite. The purpose of this study was to determine whether the effects of cholecystokinin octapeptide (CCK-8) on antropyloric motility and appetite are influenced by changes in the blood glucose concentration within the normal postprandial range. Seven healthy volunteers were studied on 4 separate days. A catheter incorporating a sleeve sensor was positioned across the pylorus, and the blood glucose was stabilized at either 4 mmol/l (2 days) or 8 mmol/l (2 days). After the desired blood glucose had been maintained for 90 min, an intravenous infusion of either CCK-8 (2 ng ⋅ kg− 1 ⋅ min− 1) or saline (control) was given for 60 min. Thirty minutes after the infusion began, the catheter was removed and subjects drank 400 ml of water with guar gum before being offered a buffet meal. The amount of food consumed (kcal) was quantified. The order of the studies was randomized and single-blinded. There were fewer antral waves at a blood glucose of 8 than at 4 mmol/l during the 90-min period before the infusions ( P < 0.05) and during the first 30 min of CCK-8 or saline infusion ( P = 0.07). CCK-8 suppressed antral waves ( P < 0.05), stimulated isolated pyloric pressure waves (IPPWs) ( P < 0.01), and increased basal pyloric pressure ( P < 0.005) compared with control. During administration of CCK-8, basal pyloric pressure ( P < 0.01), but not the number of IPPWs, was greater at a blood glucose of 8 mmol/l than at 4 mmol/l. CCK-8 suppressed the energy intake at the buffet meal ( P < 0.01), with no significant difference between the two blood glucose concentrations. We conclude that the acute effect of exogenous CCK-8 on basal pyloric pressure, but not appetite, is modulated by physiological changes in the blood glucose concentration.

scholarly journals Profile of Blood Glucose and Insulin after Vitamin C and Vitamin E Supplementation on Active Teenagers

2018 ◽  
Vol 7 (4.26) ◽  
pp. 136
Author(s):  
Irfiansyah Irwadi ◽  
Hayuris Kinandita ◽  
Jamaluddin Mahmud ◽  
Lilik Herawati
Keyword(s):  
Blood Glucose ◽  
Vitamin E ◽  
Vitamin C ◽  
Serum Insulin ◽  
Fasting Blood Glucose ◽  
Combination Group ◽  
Control Group ◽  
High Dose ◽  
Moderate Dose ◽  
Significant Difference

Aim: Antioxidants, such as vitamin C and vitamin E, is widely used as supplements. The aim of this study is to analyze the profile of blood glucose, serum insulin, and  HOMA in active teenagers after vitamin C and vitamin E supplementation.Methods: Subjects (14-16 y.o) consisted of 12 boys and 5 girls, divided into 3 groups: control (4 boys, 2 girls), ‘moderate dose’ of vitamin C and vitamin E combination group (5 boys, 1 girls), and ‘high dose’ of vitamin C and vitamin E combination group (3 boys, 2 girls). The treatment was given for 5 days. Vitamin C and vitamin E for ‘moderate dose’ was 500mg;  200IU, and for ‘high dose’ was 1000mg; 400IU. Fasting Blood Glucose (FGB) and 1 hour BG (1hr_BG), fasting serum insulin (FSI) and 1 hour SI (1hr_SI) was collected after treatment. We also calculated the HOMA-IR and HOMA-β.Result: There was no significant difference on FBG, 1hr_BG, FSI, 1hr_SI, HOMA-IR, and HOMA-β (p≥ 0.05). However, mean FBG and 1hr_BG tended to be higher on the treatment groups. The control group had the lowest HOMA-IR and the highest HOMA-β.Conclusions: We suggest that the supplementation of vitamin C and vitamin E in active teenagers is not essential on glucose homeostasis.  

scholarly journals Guar gum and reduction of post-prandial glycaemia: effect of incorporation into solid food, liquid food, and both

1979 ◽  
Vol 41 (3) ◽  
pp. 505-510 ◽  
Author(s):  
T. M. S. Wolever ◽  
D. J. A. Jenkins ◽  
R. Nineham ◽  
K. G. M. M. Alberti
Keyword(s):  
Blood Glucose ◽  
Liquid Phase ◽  
Guar Gum ◽  
Serum Insulin ◽  
Solid Food ◽  
Liquid Food ◽  
The Difference ◽  
Peak Increase ◽  
Carbohydrate Meal

1. The influence of the dose and the form in which guar gum was given on the degree of ‘flattening’of blood glucose curves was studied in five subjects using meals of bread and soup containing 5 or 10 g guar gum.2. When 5 g guar gum was added to bread the peak increase of blood glucose was reduced by 41% (P < 0.002), with 5 g guar in soup, the reduction was 54% (P < 0.001) while a reduction of 68% (P < 0.001) was seen with 10 g guar gum (5 g in bread and 5 g in soup). The corresponding reduction in insulin peak increases were 37% (P < 0.002), 50% (P < 0.001) and 65% (P < 0.001) respectively.3. The difference between the two 5 g doses was not significant with respect to the reduction of the peak increases in blood glucose and serum insulin; however the difference between the 5 g dose in bread and the increases in blood glucose and serum insulin; however the difference between the 5 g dose in bread and the 10 g dose was significantly different (P < 0.002 for glucose, P < 0.01 for insulin).4. The results indicate that as little as 5 g guar gum may reduce the glycaemia following a 45 g carbohydrate meal, but perhaps due to earlier and more complete mixing, guar gum is most effective when added to the liquid phase of the meal.

Effect of guar on second-meal glucose tolerance in normal man

1986 ◽  
Vol 71 (1) ◽  
pp. 49-55 ◽  
Author(s):  
T. R. Trinick ◽  
M. F. Laker ◽  
D. G. Johnston ◽  
M. Keir ◽  
K. D. Buchanan ◽  
...  
Keyword(s):  
Guar Gum ◽  
Serum Insulin ◽  
Gastric Inhibitory Polypeptide ◽  
Treated Group ◽  
Glucose Absorption ◽  
Whole Body ◽  
Constant Infusion ◽  
Glucose Turnover ◽  
Oral Glucose ◽  
Significant Difference

1. Whole body glucose turnover and absorption of a 50 g glucose drink was studied in six healthy volunteers on two occasions, 4 h after a ‘breakfast’ of 50 g of glucose, mixed on one occasion with 20 g of guar gum. 2. Plasma glucose concentrations were significantly reduced with guar gum compared with those obtained without guar gum (P < 0.0001). 3. Whole body glucose turnover studied by an intravenous primed dose constant infusion technique using d-[3-3H]glucose showed no significant difference between the two groups: 353 ± 15 mmol with guar and 350 ± 9 mmol without guar. 4. Total oral glucose absorption, followed with a D-[1-14C]glucose tracer, was significantly decreased by guar treatment, being 219 ± 3 mmol with guar and 239 ± 5 mmol without guar (P < 0.05). 5. Serum insulin levels were lowered by guar treatment (P<0.05) while those of C-peptide, gastric inhibitory polypeptide, glucagon, Cortisol and pancreatic polypeptide did not differ significantly. 6. Blood lactate concentrations were raised in the guar treated group (P < 0.05) whereas pyruvate, alanine, glycerol and 3-hydroxybutyrate concentrations did not differ significantly. 7. These results support the suggestion that guar improves second-meal tolerance to glucose by decreasing absorption.

scholarly journals Effect of Chlorpromazine on Rem Rebound in Normal Volunteers

1972 ◽  
Vol 17 (6) ◽  
pp. 463-469
Author(s):  
J. Naiman ◽  
R. Poitras ◽  
F. Engelsmann
Keyword(s):  
Analysis Of Variance ◽  
Total Sleep Time ◽  
Normal Subjects ◽  
Sleep Time ◽  
Normal Volunteers ◽  
The Third ◽  
Significant Difference ◽  
Dependent Variables ◽  
Rem Latency ◽  
Main Effects

The effect of chlorpromazine on the REM deprivation rebound was studied. Five normal subjects participated in the experiment which consisted of three periods of nine nights each. The first period was without medication, the second with medication and the third again without medication. Four dependent variables — Total Sleep Time, REM latency, REM time and REM percentage — were measured in each period as follows: baseline — three nights, REM deprivation — two nights and recovery — four nights. Analysis of variance (three-way classification) was computed in order to evaluate both the main effects as well as the interaction between medication and sleep conditions. The results showed significant difference over the three conditions of sleep — baseline, REM deprivation and recovery. While there were no significant differences due to medication the replication of the measurements in the same subjects proved to be a slightly significant source of the variance of the scores in all variables except REM latency.

Correlation of Plasma Phenformin Concentration with Metabolic Effects in Normal Subjects

1980 ◽  
Vol 58 (2) ◽  
pp. 153-155 ◽  
Author(s):  
M. Nattrass ◽  
Karen Sizer ◽  
K. G. M. M. Alberti
Keyword(s):  
Blood Glucose ◽  
Plasma Concentration ◽  
Blood Lactate ◽  
Serum Insulin ◽  
Lactate Concentration ◽  
Blood Lactate Concentration ◽  
Normal Subjects ◽  
Metabolic Effects ◽  
Intermediary Metabolites ◽  
Pyruvate Ratio

1. Circulating concentrations of intermediary metabolites have been measured after administration of 50 mg of phenformin to normal subjects. 2. Phenformin caused a significant increase in blood lactate, alanine and the lactate/pyruvate ratio but did not affect blood glucose or serum insulin concentrations. 3. There was a significant correlation between the increase in blood lactate concentration after phenformin and the plasma concentration of the drug.

scholarly journals A Single Center, Open-Labeled Trial To Investigate The Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects

2021 ◽  
Author(s):  
Ching Fai Kwok ◽  
Low-Tone Ho
Keyword(s):  
Single Dose ◽  
Blood Glucose ◽  
Insulin Detemir ◽  
Safety Concern ◽  
Serum Insulin ◽  
Pharmacokinetic Profile ◽  
Significant Difference ◽  
Secondary Endpoints ◽  
Male Subjects ◽  
Comparator Trial

Abstract Backgrounds: Insulin detemir(nn304) is a long-acting insulin analogue reported to provide more predictable blood glucose level throughout the day, leading to a lower within-subject variability compared to NPH insulin. Pharmacokinetic profiles of insulin detemir had not been investigated in Taiwanese. This study was to determine whether there is a differencebetween Taiwanese subjects in pharmacokinetic profile of insulin detemir compared to Caucasian subjects.Methods: Pharmacokinetic profile of insulin detemir was measured in twenty male Taiwaneses(nn304-3023). Eligible subjects were given insulin detemir as a single dose subcutaneous injection at 0.5 U/kg body weight in the mid-thigh using NovoPen® 3 device. 32-hour serum insulin detemir concentrations were measured. Hypoglycemia and adverse events were recorded. The results were compared to data obtained from a previous trial inCaucasian subjects (nn304-1451).Results: There was no significant difference between Taiwanese (nn304-3023) and Caucasian(nn304-1451) in the primary endpoint, AUC(0–∝), and the secondary endpoints, AUC(0–24h), and t1/2. However, the secondary endpoints, Cmax was 40% higher, tmax was shorter(270.0 vs. 420.0 min) and AUC(0–5h) was 2-fold more in Taiwanese. When only male subjects were included in the comparator trial (nn304-1451), the t1/2 was significantly shorter in Taiwanese(348 min vs 404 min). There was no significant difference in the mean blood glucose concentrations between Taiwanese and Caucasian subjects. A single episode of hypoglycemia(53 mg/dL) was reported in a 24-year-old male approximately 2.5 hours after the administration of insulin detemir. He was able to treat himself for the episode.Conclusion: In this pharmacokinetic evaluation of a single dose administration of insulin detemir in Taiwanese male subjects, the AUC(0–∝), and AUC(0–24h) were not different from that of Caucasians in the comparator trial. However, insulin detemir appeared to be more rapidly absorbed in Taiwanese males. Further studies are warranted to elucidate its pharmacodynamic response and mechanisms. Finally, there was no clinically relevant safety concern raised in this study. (Funded by research grant from Novo Nordisk, Taiwan; first registration date 22/12/2011 ClinicalTrials.gov number, NCT01497587.

Auditory Selective Attention in Cerebral-Palsied Individuals

1985 ◽  
Vol 16 (4) ◽  
pp. 260-266 ◽  
Author(s):  
Lee Ann Laraway
Keyword(s):  
Selective Attention ◽  
White Noise ◽  
Normal Subjects ◽  
Auditory Selective Attention ◽  
Normal Individuals ◽  
Significant Difference

The purpose of this study was to determine whether there is a statistically significant difference between the auditory selective attention abilities of normal and cerebral-palsied individuals. Twenty-three cerebral-palsied and 23 normal subjects between the ages of 5 and 21 were asked to repeat a series of 30 items consisting of from 2 to 4 digits in the presence of intermittent white noise. Results of the study indicate that cerebral-palsied individuals perform significantly poorer than normal individuals when the stimulus is accompanied by noise. Noise was not a significant factor in the performance of the normal subjects regardless of age.

A Specific Immunologic Assay for Functional Plasminogen Activator Inhibitor 1 in Plasma – Standardized Measurements of the Inhibitor and Related Parameters in Patients with Venous Thromboembolic Disease

1992 ◽  
Vol 68 (05) ◽  
pp. 486-494 ◽  
Author(s):  
Malou Philips ◽  
Anne-Grethe Juul ◽  
Johan Selmer ◽  
Bent Lind ◽  
Sixtus Thorsen
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Normal Subjects ◽  
Tissue Type ◽  
Blood Collection ◽  
Plasminogen Activator Inhibitor 1 ◽  
Type Plasminogen Activator ◽  
Significant Difference ◽  
Activator Inhibitor ◽  
Pai 1

SummaryA new assay for functional plasminogen activator inhibitor 1 (PAI-1) in plasma was developed. The assay is based on the quantitative conversion of PAI-1 to urokinase-type plasminogen activator (u-PA)-PAI-l complex the concentration of which is then determined by an ELISA employing monoclonal anti-PAI-1 as catching antibody and monoclonal anti-u-PA as detecting antibody. The assay exhibits high sensitivity, specificity, accuracy, and precision. The level of functional PAI-1, tissue-type plasminogen activator (t-PA) activity and t-PA-PAI-1 complex was measured in normal subjects and in patients with venous thromboembolism in a silent phase. Blood collection procedures and calibration of the respective assays were rigorously standardized. It was found that the patients had a decreased fibrinolytic capacity. This could be ascribed to high plasma levels of PAI-1. The release of t-PA during venous occlusion of an arm for 10 min expressed as the increase in t-PA + t-PA-PAI-1 complex exhibited great variation and no significant difference could be demonstrated between the patients with a thrombotic tendency and the normal subjects.

Sign in / Sign up

Export Citation Format

Share Document